Plain-English translation of NCT05281809 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing CAR T-cell therapy—a treatment where doctors collect your own immune cells, reprogram them in a lab to recognize and fight cancer, and then put them back into your body. This study focuses on whether these cells can be successfully made locally (rather than sent away to a commercial facility) and given safely to people with certain types of B-cell lymphomas or leukemias. The medication is manufactured specifically from each patient's own cells.
Many patients with advanced blood cancers have exhausted standard treatment options and have a poor outlook. This trial exists to see whether making this specialized immune cell treatment locally can help patients who cannot access commercially available versions or who have limited survival prospects.
You likely qualify if…
You likely don't qualify if…
You will have blood cells collected through a process called apheresis, which takes a few hours. Your cells will then be sent to a lab where they are reprogrammed to fight cancer. While the cells are being prepared, you will receive chemotherapy to prepare your body. Once the cells are ready, you will receive them back as an infusion. You will stay in the hospital for at least two weeks for close monitoring, then have regular outpatient visits for several months, and finally longer-term follow-up visits for up to 15 years.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
United States